Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.59 |
| ▸ | CTSS | P25774 | 9/20 | 0.59 |
| ▸ | CTSL | P07711 | 2/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19227630 | 0.85 | CA1 (0.58) | CTSKCTSSCTSLCTSBAAK1 | |
| SCHEMBL24387779 | 0.84 | CTSK (0.49) | CTSKCTSSCTSLCTSBAAK1 | |
| SCHEMBL4795008 | 0.84 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL5115667 | 0.84 | CTSS (0.57) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL1722314 | 0.84 | CTSS (0.57) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL4795003 | 0.84 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL16285819 | 0.82 | CTSS (0.50) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12602587 | 0.81 | CTSK (0.59) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL16839646 | 0.81 | SYK (0.48) | CTSKCTSSCTSLCTSBAAK1 | |
| SCHEMBL31086524 | 0.81 | CYP2D6 (0.50) | CTSKCTSSCTSLCTSBAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4237086-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7144901-B2 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO.,LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-20040204368-A1 | Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1234820-A1 | OXADIAZOLE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CTSK 3605/4885CTSS 3726/4885CTSL 4434/4885 |
| US-20040204368-A1 | Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP3, CASP7 | CTSK 451/4885CTSS 36/4885CTSL 263/4885 |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ACIN1, CYCS, CASP7 | CTSK 280/4885CTSS 22/4885CTSL 302/4885 |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ACIN1, CASP7, ASNS | CTSK 370/4885CTSS 9/4885CTSL 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.